Vertex Pharmaceuticals reports third-quarter 2026 results
Vertex Pharmaceuticals reported its financial results for the third quarter of 2026, recording non-GAAP net income of $1.2 billion.
Key points
- Cash and marketable securities totaled $9.8 billion at the end of September, down from $12.3 billion at year-end 2025.
- Rising operating expenses from product development and asset integration may limit earnings growth.
Financial and operating performance
Cash and marketable securities totaled $9.8 billion at the end of September, down from $12.3 billion at year-end 2025. The decrease followed the $9.0 billion net acquisition of Crinetics Pharmaceuticals and share repurchases, partially offset by a $4.5 billion term loan.
CASGEVY revenue was $99 million, while JOURNAVX generated $58 million in the third quarter. In September, the company recorded its first $10 million in revenue from PALSONIFY, a drug acquired with Crinetics.
Cash and cash equivalents
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Shareholder risks
Rising operating expenses from product development and asset integration may limit earnings growth. Additionally, the company’s new debt structure for acquisitions impacts its liquidity.
Key events to monitor
Shareholders should watch for a U.S. regulatory decision on povetacicept, expected by November 30, 2026. The company also plans to release interim results for VX-670, a treatment for myotonic dystrophy.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Vertex Pharmaceuticals Inc / MA
A notification in your browser or on your phone when we publish about Vertex Pharmaceuticals Inc / MA. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
